Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | XBP1 | P17861 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18418020 | 0.96 | NPSR1 (0.41) | KDM4ENPSR1MAPTHPGDNPC1 | |
| SCHEMBL18418003 | 0.88 | NPSR1 (0.53) | KDM4ENPSR1MAPTHPGDNPC1 | |
| SCHEMBL18417995 | 0.88 | NPSR1 (0.53) | KDM4ENPSR1MAPTHPGDNPC1 | |
| SCHEMBL19627526 | 0.88 | NPSR1 (0.48) | KDM4ENPSR1MAPTHPGDNPC1 | |
| SCHEMBL18462326 | 0.88 | NPSR1 (0.48) | KDM4ENPSR1MAPTHPGDNPC1 | |
| SCHEMBL18422583 | 0.87 | HTT (0.57) | KDM4ENPSR1MAPTHPGDNPC1 | |
| SCHEMBL18422582 | 0.87 | HTT (0.57) | KDM4ENPSR1MAPTHPGDNPC1 | |
| SCHEMBL18417990 | 0.86 | KDM4E (0.50) | KDM4ENPSR1MAPTHPGDNPC1 | |
| SCHEMBL18417999 | 0.86 | KDM4E (0.50) | KDM4ENPSR1MAPTHPGDNPC1 | |
| SCHEMBL18417998 | 0.84 | NPSR1 (0.46) | KDM4ENPSR1MAPTHPGDNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3328819-B1 | ANTHRACENE-9, 10-DIONE DIOXIME COMPOUNDS PRODRUGS AND THEIR USES | BETA CAT PHARMACEUTICALS INC (US) | 2020-04-01 | — | — | EP | disclosed |
| US-9963475-B2 | Anthracene-9, 10-dione dioxime compound prodrugs and their uses | BETA CAT PHARMACEUTICALS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-9963475-B2 | Anthracene-9, 10-dione dioxime compound prodrugs and their uses | BETA CAT PHARMACEUTICALS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-20170334936-A1 | ANTHRACENE-9, 10-DIONE DIOXIME COMPOUND PRODRUGS AND THEIR USES | Iterion Therapeutics, Inc. | 2017-11-23 | — | — | US | disclosed |
| US-20170334936-A1 | ANTHRACENE-9, 10-DIONE DIOXIME COMPOUND PRODRUGS AND THEIR USES | Iterion Therapeutics, Inc. | 2017-11-23 | — | — | US | disclosed |
| US-9725473-B2 | Anthracene-9, 10-dione dioxime compound prodrugs and their uses | BETA CAT PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725473-B2 | Anthracene-9, 10-dione dioxime compound prodrugs and their uses | BETA CAT PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20170029450-A1 | ANTHRACENE-9, 10-DIONE DIOXIME COMPOUND PRODRUGS AND THEIR USES | Iterion Therapeutics, Inc. | 2017-02-02 | — | — | US | disclosed |
| US-20170029450-A1 | ANTHRACENE-9, 10-DIONE DIOXIME COMPOUND PRODRUGS AND THEIR USES | Iterion Therapeutics, Inc. | 2017-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029450-A1 | ANTHRACENE-9, 10-DIONE DIOXIME COMPOUND PRODRUGS AND THEIR USES | ACR, TOP2B, TOP2A | KDM4E 1909/4885NPSR1 4260/4885MAPT 4739/4885 |
| US-20170334936-A1 | ANTHRACENE-9, 10-DIONE DIOXIME COMPOUND PRODRUGS AND THEIR USES | ACR, TOP2B, TOP2A | KDM4E 1909/4885NPSR1 4260/4885MAPT 4739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.